Risk factor
Considerable default risk
Profitability factor
Strong growth
About
Insmed Incorporated, a biopharmaceutical company, develops and commercializes therapies for patients with serious and rare diseases. The company offers ARIKAYCE for the treatment of Mycobacterium avium complex lung disease as part of a combination antibacterial drug regimen for adult patients. It is also developing Brensocatib, an oral reversible inhibitor of dipeptidyl peptidase 1 for the...
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Target Price
The average target price of INSM is 218 and suggests 36% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to increas
Buy
Sell